For smaller weight transurethral resection of prostate, combined transurethral incision of bladder neck is an independent factor for less urinary retention rate. – A nation-wide database study  by Wei, Tzu-Chun et al.
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IS THERE NECESSARY TO PERFORM URETERECTOMY IN RENAL CELL
CARCINOMA TREATMENT
Hueih-Shing Hsu, Heng-Chang Chuang, Shyh-Chyi Chang, Hsu-Hsiang
Wang, I-Hung Shao. Division of Urology, Department of Surgery, Lotung
Pohai Hospital Yilan, Taiwan
Purpose: Radical nephrectomy is the standard surgical treatment of
localized renal cell carcinoma.
Is there necessary to perform ureterectomy at the same time? We chal-
lenge this question, because we have tow cases of renal cell carcinoma
received radical nephrectomy but recurrent tumor was found in the ureter
several years later.
Materials and Methods: This is a 79 years old man who received left
radical nephrectomy for renal cell carcinoma stage (T2N0M0) 4 years ago.
And he underwent hemodialysis for end stage renal disease for 5 years.
Gross hematuria was noted recently and CT scan showed left ureter tumor
in the remaining stump. Ureterectomy with bladder cuff was done and
pathology shoed transitional cell carcinoma stage T3NoMo.
Results: This is a 90 years old man who received left radical nephrectomy
for renal cell carcinoma (stage T3N0M0) 14 years ago. He suffered from
gross hematuria and CT showed left ureter tumor in the stump. Ureter-
ectomy with bladder cuff was done and pathology shoed renal cell carci-
noma stage T4N1Mo.
Conclusion: Renal cell carcinoma is not only existed in renal parenchyma
but also in collecting system. Transitional cell carcinomamay occured in the
remaining stump of ureter in uremia patient. So it is better to perform ure-
terectomy in uremia patient or the larger renal tumor closed to renal pelvis.
NDP033:
ACUTE URINARY RETENTION IN A MAN WITH PROSTATE CANCER STILL
ELIGIBLE FOR TRANSURETHRAL RESECTION OF PROSTATE
Chih-Te Lin, Chen-Pang Hou, Yu-Hsiang Lin, Ke-Hung Tsui, Phei-Lang
Chang, Chien-Lun Chen. Division of Urology, Department of Surgery,
Chang Gung Memorial Hospital at Linkou, Chang Gung University, College
of Medicine, Taoyuan, Taiwan
Purpose: To interrogate the outcome of transurethral resection of prostate
(TURP) in men with prostate cancer (PCa).
Materials and Methods: A total of 160 patients with prostate cancer un-
dergoing TURP for acute urinary retention (AUR) between 2001 and 2010
were retrospectively reviewed. Thirty-eight patients undergoing palliative
TURP (pTURP group) and the other 122 patients with newly diagnosed
prostate cancer received TURP (iTURP group) were compared. We also
included 9 patients with prostate cancer undergoing palliative cystostomy
without TURP (cystostomy group). The data, including preoperative char-
acteristics, perioperative morbidities and mortality were analyzed.
Results: Therewere no signiﬁcant differences between the 2 groups in age,
initial PSA (iPSA), operative time, incontinence rate, hospital stay or Foley
catheter duration. However, the prostate volume was higher in iTURP
group (49.31± 25.57gm) than in pTURP group (39.29 ± 18.36 gm)
(p ¼ 0.006). The mean resected weight was higher in iTURP group (14 gm)
than in pTURP group (10 gm). The pTURP group was more likely to reca-
theterization and the Foley home rate (FHR) was higher. The re-operation
rate was not signiﬁcant over two groups. There was no complication such
as transurethral resection (TUR) syndrome or perioperative death in either
group. There was no signiﬁcant difference of mortality over two groups.
Conclusion: TURP can be performed safely for relief of AUR in patients
with prostate cancer, no matter if the cancer was diagnosed before or after
surgery. The recatherization rate and FHR were higher in pTURP group,
which may be due to the palliative intent.
NDP034:
TWO RARE CASES OF PRIMARY MALIGNANAT SMALL CELL CARCINOMA
COMBINED WITH UROTHELIAL CELL CARCINOMA IN THE URETER AND
METAANALYSIS
Jhih-Cheng Wang 1,2, Li-Jing Ye 3, Zi-Ru Chen 3, Yu-Hsuan Kuo 4. 1Divisions
of Urology, Department of Surgery, Chi-Mei Medical Center, Tainan, Taiwan;2 Institution of Biomedical Engineering, National Cheng Kung University,
Tainan, Taiwan; 3Department of Pathology, Chi-Mei Medical Center, Tainan,
Taiwan; 4Division of hemato-oncology, Department of Medicine, Chi Mei
Medical Center, Tainan, Taiwan
Background: Extrapulmonary small cell carcinomas have been reported
in a variety of organs, and their incidence in the genitourinary tract is
second only to that in the gastrointestinal tract. To date, however, only a
few cases of small cell carcinoma of the ureter have been reported.
Because the extreme rarity of this combined type of carcinoma, its
clinical behavior, and effective treatment modalities have not yet been
studies well.
Cases Presentation: A 73-year-old man has a past history of prostate
adenocarcinoma, cT3aN0M0, s/p hormone therapy and radiotherapy and
regular followup at OPD. He presented with a two-month history of
painless gross hematuria. He had a smoking history of one pack (Ciga-
rettes, 20/pack) per day for over 30 years, but without having any respi-
ratory symptoms. After intravenous pyelography survey, left UPJ tumor
was suspected and diagnostic ureteronephroscopic biopsy revealed uro-
thelial carcinoma. Laparoscopic Nephroureterectomy done and pathologic
examination showed an SCC combined with a urothelial carcinoma in the
ureter.
Another patient is a 67 year-old female with a diabetes history, present
with intermittent painless gross hematuria. She also received diagnostic
ureteronephroscopic biopsy then laparoscopic nephroureterectomy with
bladder cuff done. The small cell carcinoma was diffusely positive for
neuron-speciﬁc enolase, and exhibited focal positivity for CD 56, syn-
aptophysin, chromogranin and cytokeratin 20. They were treated with
adjuvant chemotherapy, consistingof cisplatin and etopside, and has being
well, without evidence of tumor recurrence or metastasis in the 6 months
after surgery.
Conclusion: Small cell carcinoma of the ureter is rare. Combined uro-
thelial carcinoma with SCC is rarer. Although its clinical behavior and
diagnostic modalities have not been determined and it has yet to
be diagnosed immunohistopathologically, multimodality treatment
including surgery, chemotherapy and radiotherapy may improve patient
survival.LUTS
NDP035:
FOR SMALLER WEIGHT TRANSURETHRAL RESECTION OF PROSTATE,
COMBINED TRANSURETHRAL INCISION OF BLADDER NECK IS AN
INDEPENDENT FACTOR FOR LESS URINARY RETENTION RATE. e A
NATION-WIDE DATABASE STUDY
Tzu-Chun Wei 1,2, Tzu-Ping Lin 1,2, Alex T.L. Lin 1,2, Hsiao-Jen Chung 1,2, Eric
YH. Huang 1,2, Kuang-Kuo Chen 1,2. 1Department of Urology, Taipei Veterans
General Hospital, Taiwan; 2Department of Urology, School of Medicine, and
Shu-Tien Urological Institute, National Yang Ming University, Taipei, Taiwan
Purpose: If the resection weight of transurethral resection of prostate
(TURP) is smaller, acute urinary retention (AUR) after the operationmay be
a complication of great concern, especially for those without Foley indw-
elled previously. However, whether combined transurethral incision of
bladder neck (TUIBN) may reduce AUR rates after the operation is still a
question. Therefore, this article is aimed to analyze AUR rates after smaller
resectionweight of TURP in Taiwan according to the claims of the National
Health Insurance (NHI) program.
Materials and Methods: From the NHI Research Database of Taiwan, we
applied for the all the claims of patients who ever visited urology clinic
during 2006 to 2010. We received all the records of both admission and
ambulatory clinics. In Taiwan, the NHI divides TURPs into four categories
according to the resection weight (<5g, S5~15g, S15~50g, and S50g,
respectively), and the ﬁrst group (<5g) was deﬁned as “smaller weight
TURP”. AUR was deﬁned as any kind of indwelling catheterization within 2
weeks after TURP with or without TUIBN. Patients younger than 40 years
old were excluded. Patients who received TUIBN or optic or otis ure-
throtomy within 1 year before TURP and 2 months after were excluded, as
well as those who had TURPs within 2 months between each surgery or
long admission period (14 dats) after TURP. Patients who had diagnosis of
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excluded. ICD-9 codes for hypertension (HTN), diabetes mellitus (DM),
cerebral vascular disease (CVA), spinal stenosis (SS), and herniated inter-
vertebral disc (HIVD) were used for disease conﬁrmation only when the
diagnoses existed at least one year before TURP. Descriptive and compar-
ative analyses were performed.
Results: There were 2597 TURPs analyzed, including 2497 TURPs only
(group A) and 100 TURPs with combined with TUIBN (group B). The hos-
pitalization days mainly ranged from 3 to 5 days. The mean age was 72.45,
with 72.69 and 71.86 in group A and B respectively. Among all patients
included, 245 of them were associated with AUR (9.43%), with 9.69% and
3.00% in group A and B (P¼ 0.022). Patient who had previous AUR episodes
within 2 months before TURP was of 23.64%, but pre-OP AUR was not
signiﬁcantly associatedwith higher post-OPAUR rate (11.24%) than no AUR
before TURP (8.88%) (P ¼ 0.083). About co-morbidities, HTN, DM, CVA, SS,
and HIVD were not signiﬁcant risk factors for AUR after TURP (P ¼ 0.934,
0.426, 0.111, 0.976, and 0.362 respectively). In multivariate analysis, com-
bined TUIBN and younger age are the only two signiﬁcant factors associ-
ated with less AUR rates after smaller weight TURPs. (P ¼ 0.041 and 0.028
respectively)
Conclusion: In Taiwan, most patients treated with smaller weight TURP
without combined TUIBN. However, AUR rate is signiﬁcantly lower in pa-
tients receiving combined TURP with TUIBN, regardless of pre-OP Foley
indwelling or other co-morbidities. Although further randomized clinical
trials are still necessary, it implies that for patients with bladder outlet
obstruction treated with smaller resection weight of TURP, combined
TUIBN may be beneﬁcial, especially regarding the post-OP AUR episodes.
NDP036:
THE IMPACT OF PSEUDEPHEDRINE ON LOWER URINARY TRACT
SYMPTOMS IN MALE PATIENTS WITHOUT CONCOMITANT VOIDING
DYSFUNCTION
I-Hung Shao 2, Hueih-Shing Hsu 2, Shyh-Chyi Chang 2, Hsu-Hsiang
Wang 2, Heng-Chang Chuang 2, Yuan-Yun Tam1. 1Division of Urology,
Poh-Ai Hospital, Lotung, Yilan, Taiwan; 2Division of Otolaryngology, Poh-Ai
Hospital, Luodong, Yilan, Taiwan
Purpose: Pseudoephedrine is a widely used sympathomimetic amine on
patients with rhinorrhea and allergic rhinitis. The vasoconstriction effect is
believed to be principally an on a-adrenergic receptor response. Urinary
retention was considered contraindication while use on patients with
concomitant prostatic hypertrophy needs precautions. Although not one of
the most seen overall side effects, patients suffered from urinary retention
or dysuria after taking pseudoephedrine may come to urologists for help.
The study aimed to elucidate the impact of pseudephedrine on lower
urinary tract symptoms (LUTS) in patients without self-reported voiding
dysfunction.
Materials and Methods: All male patients came to our Otolaryngology
OPD for acute or chronic rhinitis was asked by doctors to make sure they
are free from voiding dysfunction by self-reported. Then patients with
voiding problems or under current medication treatment for LUTS were
excluded. Other patients were given medication according to the indi-
vidual clinical symptoms. Once pseudoephedrine was prescribed, Inter-
national Prostate Symptom Score (IPSS) questionnaires were ﬁlled in by
the patients. After treatment with pseudoephedrine for 1 week, a post-
medication IPSS questionnaire was ﬁlled for follow-up. Total 68 patients
complete the survey. Age, IPSS total score, IPSS voiding score, IPSS voiding
score, quality of life score were analyzed for correlation.
Results: The average age of total 68 patients was 38.7 year-old (15-71
year-old). The average IPSS total score before and after medication was
4.81 and 6.54 respectively. The average IPSS voiding / storage score
before medication were 2.53/2.35 and changed to 3.68/2.87 after medi-
cation. Quality of life score based on voiding condition were 1.88 and
2.03 before and after medication. Independent T-test was used to eval-
uate the predictors for worsen (deﬁned as increased IPSS-T) and stable
(deﬁned as equal or decreased IPSS-T) voiding condition. Age, pre-
medication IPSS-T and IPSS-V were signiﬁcant predictors for worsen
voiding function after taking pseudoephedrine. Quality of life score based
on voiding condition before and after medication showed no signiﬁcantly
difference.Conclusion: Patients who were self-reported free from voiding dysfunc-
tion may still suffer from increased LUTS after pseudoephedrine. Age and
pre-medication IPSS-V score could be predictors for the presence of
increased LUTS.
NDP037:
SURGICAL TREATMENT OF KETAMINE-ASSOCIATED ULCERATIVE
CYSTITIS: 8-YEAR EXPERIENCE AT CATHAY GENERAL HOSPITAL AND
REVIEW OF SERIES
Chu-Hsuan Hung, Chih-Ming Lin. Division of Urology, Department of
Surgery, Cathay General Hospital, Taiwan
Purpose: To review clinical outcomes of bladder augmentation with
ileocystoplasty for ketamine-associated ulcerative cystitis secondary to
long-term ketamine abuse.
Materials and Methods: We performed bladder augmentation with ileo-
cystoplasty for 8 patients with refractory symptoms of ketamine cystitis
(severe bladder pain, micturition pain, urgency, frequency, and/or urinary
tract damage such as hydronephrosis, and contracted bladder). Every pa-
tient had been treated conservatively with medication at OPD or referred
from other hospital. Intravenous pyelography and/or cystoscopy were
obtained before they had received surgical intervention. Their history of
ketamine consumption, symptoms, history of treatment, surgical infor-
mation and post-operative condition was obtained from medical records
and then summarized.
Results: Between 2007 and 2015, eight patients (seven males and one
female), aged 26-48 years (mean 32.7 years) underwent this procedure as
indicated. The duration of ketamine abuse ranged from 2-15 years (mean
6.8 years). Contracted bladder was noted in all patients, hydronephrosis in
2 and hydroureter in 1 under intravenous pyelography examination. Post-
operative hospitalization ranged from 12-47 days (mean 22.4 days). One
patient had ileus post colono-enteric bypass post-operative within 90
days. One had impaired renal function before surgery and received inter-
mittent hemodialysis 5 years after surgery. Most of patients followed up at
OPD within 1 year and loss follow-up after. All patients reported marked
improvement in micturition pain and urinary frequency, which greatly
enhance their quality of life.
Conclusion: This study demonstrated that bladder augmentation is
effective in relieving refractory symptoms of ketamine-associated ul-
cerative cystitis. Cessation of ketamine is the most important way to
prevent recurrence of above symptoms. This is not only a medical issue,
but timely intervention of social workers and psychological support are
also essential.
NDP038:
LONG-TERM COMBINED a eBLOCKERS AND 5- a eREDUCTASE
INHIBITOR IN BPH-THERAPEUTIC EFFECTS, ADHERENCE, AND
PREDICTORS FOR WITHDRAWAL OF MEDICATION
Hueih Ling Ong 1, Chun Hou Liao 2, Hann-Chorng Kuo 1. 1Department of
Urology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; 2Department
of Urology, Cardinal Tien Hospital and Fu-Jen Catholic University, New
Taipei, Taiwan
Purpose: To investigate the long-term therapeutic effects, patient adher-
ence of combination therapyof 5-a-reductase inhibitor (5ARI) and alpha-
blocker, and the predictors for withdrawal of medication in patients with
clinical benign prostatic hyperplasia (BPH).
Materials and Methods: BPH patients with lower urinary tract symptoms
(LUTS) under combination therapy were retrospectively analyzed from 1
to 12 years span. The therapeutics effects were assessed by International
Prostatic Symptoms Score (IPSS) and quality of life index (QoL-I), total
prostatic volume (TPV), maximum ﬂow rate (Qmax), voided volume
(VoL), prostatic speciﬁc antigen (PSA) at baseline and annually. The
reason and predictors of discontinued combination therapy were also
investigated.
Results: A total of 625 patients aged 38 to 97 (mean 73) years where
enrolled retrospectively with at least 1 year and the longest period of 12
years follow-up. The mean year follow up was 3 years. All measured pa-
rameters showed signiﬁcant improvement after combination therapy. The
